Journal ArticleDOI
Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose
Cesare Guglielmi,William Arcese,Francesco Dazzi,Ronald Brand,Donald Bunjes,Leo F. Verdonck,Anton Schattenberg,Hans-Jochem Kolb,Per Ljungman,Agnès Devergie,Andrea Bacigalupo,M. Gómez,Mauricette Michallet,Ahmet H. Elmaagacli,Alois Gratwohl,Jane F. Apperley,Dietger Niederwieser +16 more
Reads0
Chats0
TLDR
The results suggest that the first DLI dose should not exceed 0.2 x 10(8) mononuclear cells/kg, and lower ICD was associated with less GVHD, less myelosuppression, same response rate, better survival, better failure-free survival, and less DLI-related mortality.About:
This article is published in Blood.The article was published on 2002-07-15. It has received 178 citations till now. The article focuses on the topics: Transplantation & Donor lymphocyte infusion.read more
Citations
More filters
Journal ArticleDOI
Chronic myeloid leukaemia
TL;DR: Imatinib, an inhibitor of BCR-ABL tyrosine kinase, has revolutionised treatment of this disease, and is now recommended as standard treatment for chronic-phase CML.
Journal ArticleDOI
Graft-versus-leukemia effects of transplantation and donor lymphocytes
TL;DR: It is learned from adoptive immunotherapy of viral diseases and HLA-haploidentical stem cell transplantation that T-cell memory may be essential for the effective treatment of leukemia and other malignancies.
Journal ArticleDOI
Graft-versus-leukemia reactions in allogeneic chimeras
Hans-Jochem Kolb,Hans-Jochem Kolb,Christoph Schmid,Christoph Schmid,A. John Barrett,A. John Barrett,Dolores J. Schendel,Dolores J. Schendel +7 more
TL;DR: It is demonstrated that the GVL effect of DLT is most effective in chronic myelogenous leukemia (CML), whereas it is less pronounced in acute leukemia and myeloma, and new approaches for adoptive immune therapy of leukemia, which promise a better prognosis for these patients are being developed.
Journal ArticleDOI
Sequential Regimen of Chemotherapy, Reduced-Intensity Conditioning for Allogeneic Stem-Cell Transplantation, and Prophylactic Donor Lymphocyte Transfusion in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome
TL;DR: Outcome of patients with refractory disease or with complex cytogenetic aberrations was identical to that of better prognostic subgroups, and Sequential use of intensive chemotherapy, RIC transplantation, and pDLT represents a promising approach to the treatment of high-risk AML and MDS.
Journal ArticleDOI
Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
Alois Gratwohl,Ronald Brand,Jane F. Apperley,Charles Crawley,Tapani Ruutu,Paolo Corradini,Enric Carreras,Agnès Devergie,Cesare Guglielmi,H. J. Kolb,Dietger Niederwieser,Marrow Transplantation +11 more
TL;DR: Data from 592 teams in 42 European countries described their use of HSCT for CML from 1990 to 2004 to describe the current status of this option and the outcome a patient can expect today provide an objective basis for decision making.
References
More filters
Journal ArticleDOI
Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors.
Glucksberg H,Rainer Storb,Alexander Fefer,C. D. Buckner,Paul E. Neiman,Clift Ra,Lerner Kg,Thomas Ed +7 more
TL;DR: The results show that despite histocompatibility matching and methotrexate therapy, GVHD remains a serious and often fatal complication of marrow transplantation.
Journal ArticleDOI
Graft-Versus-Leukemia Effect of Donor Lymphocyte Transfusions in Marrow Grafted Patients
Hans-Jochem Kolb,A Schattenberg,JM Goldman,B Hertenstein,N Jacobsen,W Arcese,P Ljungman,A Ferrant,L Verdonck,D Niederwieser +9 more
TL;DR: Donor lymphocyte transfusions exert strong effects against myeloid forms of leukemia and induce durable remissions in CML.
Journal ArticleDOI
Donor Leukocyte Transfusions for Treatment of Recurrent Chronic Myelogenous Leukemia in Marrow Transplant Patients
Hans-Jochem Kolb,J. Mittermüller,Ch. Clemm,Ernst Holler,Georg Ledderose,G. Brehm,M.U. Heim,Wolfgang Wilmanns +7 more
TL;DR: Three patients with hematologic relapse after bone marrow transplantation for chronic myelogenous leukemia were treated with interferon alpha and transfusion of viable donor buffy coat and had complete hematological and cytogenetic remission, which persisted 32 to 91 weeks after treatment, an example of adoptive immunotherapy without cytoreductive chemotherapy or radiotherapy in human chimeras.
Journal ArticleDOI
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
Robert H. Collins,Ofer Shpilberg,William R. Drobyski,D L Porter,Sergio Giralt,R Champlin,S A Goodman,S N Wolff,W Hu,Catherine M. Verfaillie,Alan F. List,William S. Dalton,N Ognoskie,Angela Chetrit,Joseph H. Antin,John Nemunaitis +15 more
TL;DR: DLI results in complete remissions in a high percentage of patients with relapsed chronic-phase CML, and acute and chronic GVHD post-DLI were highly correlated with disease response (P < .00001).
Journal ArticleDOI
Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease
Stephen Mackinnon,Esperanza B. Papadopoulos,MH Carabasi,L Reich,Nancy H. Collins,Farid Boulad,Hugo Castro-Malaspina,Barrett H. Childs,Alfred P. Gillio,Nancy A. Kernan +9 more
TL;DR: The dose of donor leukocytes or T cells used may be important in determining both the GVL response and the incidence of GVHD, and 15 of the 17 evaluable patients have become BCR-ABL negative by PCR.